Patents Assigned to Merck
  • COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE
    Publication number: 20190218223
    Abstract: Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.
    Type: Application
    Filed: August 10, 2017
    Publication date: July 18, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jared N. Cumming, Kevin D. Dykstra, Alan Hruza, Derun Li, Hong Liu, Haiqun Tang, Brandon M. Taoka, Andreas Verras, Shawn P. Walsh, Wen-Lian Wu
  • DRUG DELIVERY SYSTEM FOR THE DELIVERY OF INTEGRASE INHIBITORS
    Publication number: 20190216725
    Abstract: This invention relates to novel implant drug delivery systems for long-acting delivery of integrase inhibitors. These compositions are useful for the treatment or prevention of human immunodeficiency virus (HIV) infection.
    Type: Application
    Filed: September 15, 2017
    Publication date: July 18, 2019
    Applicant: MERCK SHAPR & DOHME CORP.
    Inventors: Stephanie E. Barrett, Marian E. Gindy, Steven J. Henry, Seth P. Forster, Ryan S. Teller, Jay A. Grobler
  • Methods of immunization with varicella zoster virus antigen
    Patent number: 10350289
    Abstract: The present invention relates to a method of vaccinating a patient against varicella zoster virus (VZV) by delivery of an effective amount of a live attenuated VZV vaccine to the epidermis or the dermis of a patient's skin at a depth of between about 100 and about 700 microns from the surface of the skin, which is useful for preventing herpes zoster or reducing the severity or duration thereof. In embodiments of the invention, the patient is 50 years of age or older and has been previously exposed to VZV. The invention also relates to a method of preventing VZV infection in an individual who was not previously infected with VZV comprising administering an effective amount of a live attenuated VZV vaccine to the epidermis or the dermis of the individual's skin at a depth of between about 100 and about 700 microns from the surface of the skin.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: July 16, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Brian K. Meyer, Robert K. Evans, Channing R. Beals, David C. Kaslow
  • Materials for electronic devices
    Patent number: 10355223
    Abstract: The application relates to compounds having functional substituents in a specific spatial arrangement, to devices comprising same, and to the preparation and use thereof.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: July 16, 2019
    Assignee: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Tobias Grossmann, Anja Jatsch, Thomas Eberle, Jonas Valentin Kroeber, Christof Pflumm, Lars Dobelmann
  • Compounds and organic electronic devices
    Patent number: 10355217
    Abstract: The present invention relates to certain fluorenes, to the use of the compounds in an electronic device, and to an electronic device comprising at least one of these compounds. Furthermore, the present invention relates to a process for the preparation of the compounds and to a formulation and composition comprising one or more of the compounds.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: July 16, 2019
    Assignee: Merck Patent GmbH
    Inventors: Jochen Pfister, Frank Stieber, Elvira Montenegro, Teresa Mujica-Fernaud, Frank Voges
  • Factor IXa inhibitors
    Patent number: 10351558
    Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: July 16, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Dongfang Meng, Hong Li, Meng Yang, Manuel de Lera Ruiz, Sunita V. Dewnani, Tianying Jian, Dann L. Parker, Jr., Ting Zhang, Louis-Charles Campeau, Harold B. Wood, Jiayi Xu, Richard Berger, Jane Yang Wu, Robert K. Orr, Shawn P. Walsh, Bart Harper
  • 6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor
    Patent number: 10351564
    Abstract: The present invention is directed to 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: July 16, 2019
    Assignee: Merck Sharop & Dohme, Corp.
    Inventors: Xiaolei Gao, Sandra L. Knowles, Michael Man-Chu Lo, Robert D. Mazzola, Jr.
  • Compounds for electronic devices
    Patent number: 10351557
    Abstract: The present invention relates to compounds of the formula (I), to the use of compounds of the formula (I) in electronic devices, and to electronic devices containing one or more compounds of the formula (I). The invention furthermore relates to preparation processes for compounds of the formula (I) and to formulations comprising one or more compounds of the formula (I).
    Type: Grant
    Filed: May 23, 2011
    Date of Patent: July 16, 2019
    Assignee: Merck Patent GmbH
    Inventors: Rocco Fortte, Christof Pflumm, Constanze Brocke, Amir Hossain Parham
  • Electrophoretic fluids
    Patent number: 10353265
    Abstract: This invention relates to electrophoretic fluids, the use of these fluids for the preparation of an electrophoretic display device, and electrophoretic displays comprising such fluids.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: July 16, 2019
    Assignee: Merck Patent GmbH
    Inventors: Nils Greinert, Thomas Bauer, Matthias Koch, Wolfgang Hechler
  • Liquid-crystalline medium
    Patent number: 10351771
    Abstract: The invention relates to a liquid-crystalline medium comprising at least one compound of the formula I, in which R1 has the meanings indicated in Claim 1, and to the use thereof in liquid-crystalline media and in electro-optical liquid-crystal displays.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: July 16, 2019
    Assignee: Merck Patent GmbH
    Inventors: Mark Goebel, Lars Lietzau, Sabine Schoen, Andreas Pohle
  • ORGANIC SEMICONDUCTING COMPOUNDS
    Publication number: 20190214581
    Abstract: The invention relates to novel organic semiconducting compounds containing a polycydic unit, to methods for their preparation and educts or intermediates used therein, to compositions, polymer blends and formulations containing them, to the use of the compounds, compositions and polymer blends as organic semiconductors in, or for the preparation of, organic electronic (OE) devices, especially organic photovoltaic (OPV) devices, perovskite-based solar cell (PSC) devices, organic photodetectors (OPD), organic field effect transistors (OFET) and organic light emitting diodes (OLED), and to OE, OPV, PSC, OPD, OFET and OLED devices comprising these compounds, compositions or polymer blends.
    Type: Application
    Filed: August 18, 2017
    Publication date: July 11, 2019
    Applicant: MERCK PATENT GMBH
    Inventors: Graham MORSE, Lana NANSON, William MITCHELL, Michal KROMPIEC, Mansoor D'LAVARI, Agnieszka PRON
  • MIXTURE FOR OPTICAL DEVICES
    Publication number: 20190211259
    Abstract: The present invention relates to mixture comprising a semiconductor nanocrystal, optical medium, optical device and to fabrication thereof, the present invention further relates to use of mixture and to use of optical medium in an optical device.
    Type: Application
    Filed: August 18, 2017
    Publication date: July 11, 2019
    Applicant: MERCK PATENT GMBH
    Inventors: Sanaa KHALIL, Ehud SHAVIV
  • DEVICE FOR CONTROLLING TRANSMISSION OF RADIATION
    Publication number: 20190212601
    Abstract: Device for controlling transmission of radiation, comprises a first substrate comprising a first conductive layer; a second substrate comprising a second conductive layer; an active layer positioned between the first and second conductive layers for controlling the transmission of radiation by altering its light transmissivity dependent on a voltage applied to the first and second conductive layers; a first contact providing a first electrical connection to the first conductive layer; a first portion of an adhesive or solder for attaching a first proximal end of the first contact to the first conductive layer; a second contact providing a second electrical connection to the second conductive layer; and a second portion of adhesive or solder for attaching a second proximal end of the second contact to the first or second conductive layer.
    Type: Application
    Filed: May 15, 2017
    Publication date: July 11, 2019
    Applicant: Merck Patent GmbH
    Inventors: Ties de JONG, Casper van OOSTEN
  • TABLET FORMULATION FOR CGRP ACTIVE COMPOUNDS
    Publication number: 20190209478
    Abstract: The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): wherein “Ra” is independently —H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.
    Type: Application
    Filed: November 2, 2018
    Publication date: July 11, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Mary Ann Johnson, Leonardo Resende Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, JR., Rebecca Nofsinger, Melanie Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
  • A PHOTOSENSITIVE COMPOSITION, COLOR CONVERTING MEDIUM, OPTICAL DEVICES AND METHOD FOR PREPARING THE THEREOF
    Publication number: 20190211266
    Abstract: The present invention relates to a photosensitive composition, and a color conversion medium. The present invention further relates to a use of the photosensitive composition in a color conversion medium fabrication process, and to a use of the color conversion medium in an optical device. The invention furthermore relates to an optical device and method for preparing the color conversion medium and the optical device.
    Type: Application
    Filed: July 27, 2017
    Publication date: July 11, 2019
    Applicant: Merck Patent GmbH
    Inventors: Yuki HIRAYAMA, Tadashi KISHIMOTO, Masayoshi SUZUKI, Daishi YOKOYAMA, Katsuto TANIGUCHI, Teruaki SUZUKI
  • Diagnostic Anti-PD-L1 Antibody and Use Thereof
    Publication number: 20190211104
    Abstract: The present invention provides for an antibody or antigen-binding fragment thereof which binds to an epitope within human PD-L1 with high specificity and reproducibility. The inventive antibody or antigen-binding fragment thereof may be used in assessing PD-L1 expression in tissue samples to aid in patient stratification. The present invention further provides methods of producing the inventive antibody.
    Type: Application
    Filed: September 20, 2017
    Publication date: July 11, 2019
    Applicants: Merck Patent GmbH, Pfizer Inc.
    Inventors: Claudia WILM, Klaus SCHNEIDER, Heike DAHMEN
  • IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS
    Publication number: 20190211013
    Abstract: Compounds of the formula (I), in which R1, R3, Het1 and HET have the meanings given in Claim 1, are ATM kinase inhibitors and can be employed, inter alia, for the treatment of cancer.
    Type: Application
    Filed: March 14, 2019
    Publication date: July 11, 2019
    Applicant: Merck Patent GmbH
    Inventors: Thomas FUCHSS, Kai SCHIEMANN
  • Device for controlling the passage of energy, containing a dichroic dye compound
    Patent number: 10344217
    Abstract: The present application relates to a device for regulating the passage of energy from an outside space into an inside space, where the device comprises a switching layer comprising one or more dichroic dyes of a formula (I) or formula (II).
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: July 9, 2019
    Assignee: MERCK PATENT GMBH
    Inventors: Peer Kirsch, Alexander Hahn, Andreas Ruhl, Susann Beck, Junyou Pan, Michael Junge, Andreas Beyer, Ursula Patwal
  • Liquid crystal display device and method for manufacturing liquid crystal display device
    Patent number: 10344216
    Abstract: The present invention provides a liquid crystal display device that is less prone to display defects and a decrease in the voltage holding ratio regardless of the presence or absence of an alignment film. The liquid crystal display device includes: a pair of substrates; a liquid crystal layer containing a liquid crystal material between the substrates; and a polymer layer for controlling alignment of liquid crystal molecules on a surface of at least one of the substrates, the substrates being substantially free of an alignment film in outermost surfaces thereof, the polymer layer being formed by polymerization of at least two kinds of radical polymerizable monomers in the liquid crystal layer, at least one of the radical polymerizable monomers being a compound having a structure that creates a ketyl radical as a result of hydrogen abstraction induced by light radiation.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: July 9, 2019
    Assignee: MERCK PATENT GMBH
    Inventors: Masayuki Kanehiro, Masanobu Mizusaki
  • Particles for electrophoretic displays
    Patent number: 10344167
    Abstract: This invention relates to polymer particles, a process for their preparation, the use of these particles for the preparation of an electrophoretic device, electrophoretic displays comprising such particle, and new polymerizable dyes.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: July 9, 2019
    Assignees: Merck Patent GmbH, The Queen's University of Belfast
    Inventors: Jonathan Henry Wilson, Louise Diane Farrand, Anthony Lawrence, Sarah Youngs